Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH
Top

01-04-2019 | Non-small-cell lung cancer | Video | Article

Researcher comment: TATTON trial – Investigating savolitinib plus osimertinib in EGFR-mutated, MET-amplified NSCLC

print
PRINT
insite
SEARCH

Advisory board member and study author Lecia Sequist takes us through the findings of the savolitinib plus osimertinib cohort of the phase Ib TATTON trial of advanced non-small-cell cancer patients who have developed resistance to EGFR inhibitor therapy (4:48).

External Content

Click Play to display this content and agree to third party cookies. (>)

Update your current cookie settings.

print
PRINT
Image Credits